Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company developing allogeneic CAR T (AlloCAR T) therapies for cancer and autoimmune disease. The ALLO news feed on Stock Titan aggregates company announcements, clinical updates, and regulatory disclosures so readers can follow how its AlloCAR T pipeline progresses through development.
News about Allogene frequently highlights key milestones in its major programs. For oncology, updates include progress in the pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma, including trial design changes, site activations, and planned interim analyses focused on minimal residual disease (MRD) conversion. For autoimmune disease, releases cover the Phase 1 RESOLUTION trial of ALLO-329, a dual CD19/CD70 AlloCAR T candidate that incorporates the company’s Dagger® technology and is being studied across multiple rheumatologic indications.
Investors and observers can also find news on ALLO-316 in renal cell carcinoma through the TRAVERSE trial, including early clinical response data and discussions with regulators about potential pivotal development. Additional items include quarterly financial results, cash runway commentary, participation in investor and medical conferences, and 8-K summaries of material events such as changes in lymphodepletion strategy or intellectual property developments involving licensed TALEN-based gene-editing technology.
By following ALLO news, readers can track clinical catalysts, safety and biomarker findings, regulatory interactions, and corporate updates that may influence perceptions of Allogene’s AlloCAR T platform and its potential applications in hematologic malignancies, solid tumors, and autoimmune diseases.
Allogene Therapeutics reported promising results from its Phase 1 trials (ALPHA and ALPHA2) of AlloCAR T therapy for treating large B-cell lymphoma and follicular lymphoma. The therapy exhibited a 44% complete response rate in large B-cell lymphoma patients, with no relapses observed in those achieving complete response at six months. The regimen was well tolerated, showing low adverse event rates. Allogene plans to initiate a pivotal Phase 2 trial in relapsed/refractory large B-cell lymphoma, contingent upon discussions with the FDA, aiming for accelerated patient treatment timelines.
Allogene Therapeutics (Nasdaq: ALLO) announced a conference call scheduled for December 13, 2021, at 1:30 PM PT/4:30 PM ET. The call will cover data from the ALPHA, ALPHA2, and UNIVERSAL Phase 1 trials concerning their AlloCAR T™ therapies for treating relapsed/refractory non-Hodgkin lymphoma and multiple myeloma. The live call can be accessed via phone or webcast, with a replay available for 30 days on their website. Allogene specializes in developing innovative, scalable cell therapies for cancer.
Allogene Therapeutics (Nasdaq: ALLO), a biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer, announced its participation in five virtual investor conferences. These include Cowen's IO Next Summit on November 15, Stifel's Healthcare Conference on November 16, and others through December 6. Webcasts will be available on Allogene's website, providing investors with insights into the company's innovative therapies and future developments.
Allogene Therapeutics (ALLO) recently announced updates surrounding its AlloCAR T™ clinical trials, including presentations at the upcoming American Society of Hematology annual meeting.
The ALPHA2 trial showcased the benefits of consolidation dosing with ALLO-501A in relapsed/refractory large B-cell lymphoma. The company reported a third-quarter net loss of $78.2 million and ended the quarter with $862 million in cash and equivalents. Ongoing discussions with the FDA aim to resolve a clinical hold on its trials following a chromosomal abnormality report.
Allogene Therapeutics (ALLO) announced the selection of three abstracts for oral and poster presentations at the 63rd Annual Meeting of the American Society of Hematology (ASH) on December 13, 2021. The presentations will showcase updated data from the ALPHA2 study of ALLO-501A in large B-cell lymphoma, the ALPHA study of ALLO-501 in non-Hodgkin lymphoma, and the UNIVERSAL study of ALLO-715 in multiple myeloma. These findings highlight the potential of AlloCAR T therapies in treating relapsed/refractory blood cancers, with encouraging efficacy and manageable safety profiles reported.
Allogene Therapeutics (ALLO) will release its third quarter 2021 financial results on November 4, 2021, after market close. A conference call and webcast will follow at 2 PM PT/5 PM ET. Allogene, based in South San Francisco, focuses on developing allogeneic CAR T (AlloCAR T™) therapies for cancer, aiming to provide readily available cell therapy to patients. Shareholders can access the live webcast on the company's website, with a replay available for 30 days.
Allogene Therapeutics (Nasdaq: ALLO) announced that the FDA has placed a clinical hold on its AlloCAR T trials following the detection of a chromosomal abnormality in a patient treated with ALLO-501A. The patient showed a partial response but developed progressive pancytopenia and aplastic anemia, leading to an investigation into the abnormality's clinical significance. The company believes data from the ALPHA trials support a favorable profile for ALLO-501A, and it is working closely with the FDA to address any potential clinical implications.
Allogene Therapeutics (Nasdaq: ALLO) announced the addition of Dr. Jae Park, a leading expert in cell therapies, to its Scientific Advisory Board. Dr. Park, associated with Memorial Sloan Kettering Cancer Center, has extensive experience in CAR T therapies and is the principal investigator for multiple clinical trials. This appointment aims to enhance Allogene's research capabilities in developing allogeneic CAR T (AlloCAR T™) therapies for various cancers. The company seeks to leverage Dr. Park's expertise to advance its initiatives in treating blood cancers and solid tumors.
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company, announced its participation in two virtual investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 4:00 AM PT. The second is the BofA Global Research Global Healthcare Conference on September 16, 2021, at 10:25 AM PT. Webcasts will be available on their website following the events. Allogene specializes in allogeneic CAR T therapies aimed at making cell therapy more accessible to patients worldwide.
Allogene Therapeutics announced that the FDA granted orphan-drug designation (ODD) to its ALLO-715 therapy for multiple myeloma. This follows the previous Regenerative Medicine Advanced Therapy (RMAT) designation received in April 2021. The Phase 1 UNIVERSAL trial showed ALLO-715 can achieve clinical responses without the need for bridging therapy. The company plans to update on the trial by the end of 2021. With ODD, the therapy is entitled to various development incentives, including potential marketing exclusivity.
FAQ
What is the current stock price of Allogene Therapeutics (ALLO)?
What is the market cap of Allogene Therapeutics (ALLO)?
